Amsbio reports how researchers at the Graduate School of Medicine, Kyoto University (Japan) have cultured patient-derived colorectal cancer cells in 3D using their MatriMix 511 extracellular matrix (ECM).
In this study** the researchers demonstrated that MatriMix supported robust cancer organoid formation, and that the organoids retained biologically relevant differences between tumour stages. By comparison, alternative matrices evaluated showed limited or no metastatic marker expression. The researchers concluded that MatriMix offers the ability to…
In the race to bring new therapeutics to market, the biggest hurdles aren’t just scientific—they’re operational. Fragmented data and information fatigue can slow down even the most promising pipelines.
To help biotech leaders bridge these gaps, Digital Science has launched a comprehensive resource hub focused on Advancing R&D Excellence. This suite of resources provides the framework needed to make confident, evidence-based decisions at every stage of discovery.
Inside the hub, you’ll find:
📘 The White Paper: A deep dive into "Structured Intelligence," exploring how AI is…
Tony JonesCEO, One Nucleus
Springing Forward in 2026 As the temperatures rise, flowers begin to bloom, and the deal flow reports keep coming; it feels like biotech may have a spring in its step. April storms and showers to dampen the mood are circling for many still; however, it is far from a universal bed of roses.
Thirty-six investment rounds were announced during Q1/2026, amounting to nearly £0.5Bn venture investment across the London and Cambridge areas alone in the sector. Notable rounds were secured by Mestag Therapeutics, Nuclera, Tenpoint…
Enables expression of active GPCRs in 48 hours
Panel supports screening to scale-up on eProtein Discovery
Cambridge, UK, and Boston MA, USA, 30 March 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery™ membrane protein workflow capabilities1, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of…
Cambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long, interactive festival with Oxford and London for the very first time. The Cambridge-Oxford-London corridor is widely regarded as one of the most productive life sciences clusters in the world, home to hundreds of biotechnology companies, globally recognised research institutions and a rapidly expanding venture capital ecosystem. Building on last year’s event, which attracted more than 4,000 attendees across 25+ venues and 200+ sessions, CWOW 2026 will convene investors,…
by Alicia Gailliez, Business Development Manager, One Nucleus
Breakthroughs are accelerating across therapeutics, data platforms, regulatory systems and business models. Yet challenges remain in how we develop and scale innovation within an increasingly complex landscape. Addressing these challenges requires collaboration across the life science ecosystem.
ON Helix brings together this breadth and diversity, connecting biotech innovators, pharma, academia, service providers and investors to create an environment for meaningful peer-to-peer learning and deal-making. It is through these…
by Alicia Gailliez, Business Development Manager, One Nucleus
The winners of the Boston Bootcamp 2026 have been announced! Congratulations to ExpressionEdits, Monument Therapeutics, Profionics, and Stick Therapeutics. These four standout companies impressed a panel of esteemed UK and US judges during the online presentation session on 24 February, where 16 companies each pitched their vision in a 5-minute slot.
With the competition now moving ever closer towards the Boston visit (27–30 April), the focus shifts to preparatory sessions with Bootcamp supporters and sponsors. These sessions are…
Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform
Cambridge, UK, 31 March 2026: Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP). The fundraise was led by Parkwalk, and joined by The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, and Start Codon. The investment will facilitate commercial…
Rebrand follows appointment of new leadership as company drives commercialization of INDUCE-seq® platform to address regulatory gaps in off-target reporting for gene editing programs
Cambridge, UK, 31 March 2026 – Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today introduced new branding and comprehensive website as part of its strategic repositioning. At a time where the gene editing industry is facing increasing regulatory demands for genome-wide off-target data, the update has…
In this episode, host Sonjoy Brahma, VP of Clinical Operations at tranScrip, is joined by Joab Williamson of Faron Pharmaceuticals to explore the operational realities of working within small emerging biotech companies. They discuss the challenges of rare oncology development, how cash runway and clinical milestones shape strategy, and why flexibility, external expertise and careful planning are essential to balanced decision-making. Together, they share practical insights into managing risk, controlling costs and advancing clinical programmes with confidence in a resource-constrained…